Developing cancer therapies for patients in need of new options
Australis brings you AUS_001
Let’s create a world where fewer children and adults suffer.
"
Found in Nature. Backed by Science.
Encouraging pre-clinical efficacy and safety data.
Global clinical development strategy.
Developing an oral formulation to potentially allow for patient dosing at home.
Who is Australis?
Australis is a global biopharmaceutical company deeply driven to bring new therapies to cancer patients in need. Our in-house research is centerd around our laboratory in Simi Valley, California, by a team of dedicated PhD scientists.
Our third-party research is performed and reviewed by esteemed professionals worldwide.
Why AUS_001?
Vetted by scientists and doctors
We have partnered with esteemed professionals worldwide to review and perform research.
Proven to target hard-to-treat cancers
AUS_001 shows strong pre-clinical efficacy against a wide range of cancers, including those typically resistant to traditional treatments. In vitro data reveals that AUS_001 has effectively targeted 24 types of cancer.
Pre-Clinical safety data
On average 20x more of AUS_001 is needed to inhibit the growth of healthy vs. neoplastic cells, indicating an encouraging safety margin.
Global partners
Our story, our nature
An abundance of vitro and in vivo studies unveiled encouraging efficacy in many types of cancers and we are preparing to enter clinical trials.
Nature's gift
Kangaroo Island’s unique biodiversity hosts a special type of ground-foraging bee, unique to Kangaroo Island. By studying the island’s bees, Australis scientists discovered a resin in local grass that was only produced to defend against kangaroos. The bees harvested the resin to make propolis to disinfect their hives. That propolis contained what is now AUS_001.
0%
Of all medicines were discovered in plant species.
0%
Of earth’s plants have been studied for treatments.
Data from our tests
AUS_001 has demonstrated very encouraging preclinical data.
These are our results so far:
In Vitro
High potency against 24 types of cancer.
In Vivo
Strong efficacy against seven cancers to date, with encouraging safety data, including:
Breast cancer
Pancreatic cancer
Bladder cancer
Melanoma
Kidney cancer
Lung cancer
Glioblastoma
We’ve been looking 40 years for a drug like this to replace the Taxol family.
"- Leading researcher at the National Cancer Institute
Our timeline
We’ve come a long way since that day on Kangaroo Island back in the 2000s.
With your help, we can make even greater progress to get AUS_001 into the hands of those who need it.
2019-01-01
2009
2019-01-01
2011
2019-01-01
2012
2019-01-01
2015
2019-01-01
2019
2019-01-01
2020
2019-01-01
2021
2019-01-01
2022
2019-01-01
2023
2019-01-01
2024
2019-01-01
2025
What’s next?
With AUS_001 planned for clinical trials by the end of 2025, we’re excited to get AUS_001 to the people who need it.
But we can’t do it alone. We need your investment to take the next step in developing and delivering the groundbreaking AUS_001.
What’s next?
With AUS_001 planned for clinical trials by the end of 2025, we’re excited to get AUS_001 to the people who need it.
But we can’t do it alone. We need your investment to take the next step in developing and delivering the groundbreaking AUS_001.
Join us on this important journey to find new therapies for patients with cancer
We are seeking investors and partners to join us in this mission. For more information, details on ongoing studies, and next steps, please reach out to us.